Evidence map›Paper›PMID 28102115›Full record

ReviewThe British journal of nutrition2017

Can probiotics modulate human disease by impacting intestinal barrier function?

Peter A Bron, Michiel Kleerebezem, Robert-Jan Brummer, Patrice D Cani, Annick Mercenier, Thomas T MacDonald, Clara L Garcia-Ródenas, Jerry M Wells

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The British journal of nutrition, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06491342 (PROBIOTIC SUPPLEMENT VERSUS PLACEBO FOR DECREASE STEATOSIS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE), which is not on this map. Cited by 243 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
243citing papers in PubMed, 11 pooled it
17.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06491342 nacompletednot on this mapstarted 2024, after this paper: background citation

Probiotic supplement versus placebo for decrease steatosis in metabolic dysfunction-associated steatotic liver disease (masld): a multicenter, randomized, double-blind, placebo-controlled trial

TypeinterventionalSponsorPhramongkutklao College of Medicine and HospitalRan2024 to 2025Enrolled90ConditionsFatty Liver, NonalcoholicArmsProbiotic, Placebo
3 · Its place in the literature

Who cites it

243 citing papers in PubMed, 11 syntheses or guidelines pooled it, 467 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

183 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 5 countries.

Peter A Bron1NIZO Food Research and BE-Basic Foundation,Kernhemseweg 2,6718ZB Ede,The Netherlands.
Michiel Kleerebezem2Wageningen University,Host Microbe Interactomics Group,De Elst 1,6708WD Wageningen,The Netherlands.
Robert-Jan Brummer3Faculty of Medicine and Health,Örebro University,Fakultetsgatan 1,SE-701 82 Örebro,Sweden.
Patrice D Cani4Metabolism and Nutrition Research Group,WELBIO - Walloon Excellence in Life Sciences and BIOtechnology,Louvain Drug Research Institute,Université catholique de Louvain,Avenue E. Mounier,73 B1.73.11,1200 Brussels,Belgium.ORCID 0000-0003-2040-2448
Annick Mercenier5Nestlé Research Center,Nutrition and Health Research,route du Jorat 57,1000 Lausanne 26,Switzerland.
Thomas T MacDonald6Barts and The London school of Medicine and Dentistry,Blizard Institute,Queen Mary University of London,Mile End Road,London E1 4NS,UK.
Clara L Garcia-Ródenas5Nestlé Research Center,Nutrition and Health Research,route du Jorat 57,1000 Lausanne 26,Switzerland.
Jerry M Wells2Wageningen University,Host Microbe Interactomics Group,De Elst 1,6708WD Wageningen,The Netherlands.
Nestlé (Switzerland) · CHWageningen University & Research · NLNederlands Instituut Voor Zuivel Oonderzoek · NLÖrebro University · SEQueen Mary University of London · GBWalloon Excellence in Lifesciences and Biotechnology · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intestinal barrier integrity is a prerequisite for homeostasis of mucosal function, which is balanced to maximise absorptive capacity, while maintaining efficient defensive reactions against chemical and microbial challenges. Evidence is mounting that disruption of epithelial barrier integrity is one of the major aetiological factors associated with several gastrointestinal diseases, including infection by pathogens, obesity and diabetes, necrotising enterocolitis, irritable bowel syndrome and inflammatory bowel disease. The notion that specific probiotic bacterial strains can affect barrier integrity fuelled research in which in vitro cell lines, animal models and clinical trials are used to assess whether probiotics can revert the diseased state back to homeostasis and health. This review catalogues and categorises the lines of evidence available in literature for the role of probiotics in epithelial integrity and, consequently, their beneficial effect for the reduction of gastrointestinal disease symptoms.

Indexed as

AnimalsHumansIntestinal DiseasesIntestinesProbioticsCD Crohn’s diseaseGastrointestinal disordersGut barrierGut microbiotaImmunityNEC necrotising enterocolitisProbioticsTJ tight junctionTLR Toll-like receptorUC ulcerative colitis

Identifiers

PMID28102115
PMCPMC5297585
OpenAlexW2573938105

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.